Graphene Oxide Decorated with Ru(II)–Polyethylene Glycol Complex for Lysosome-Targeted Imaging and Photodynamic/Photothermal Therapy

Zhang, Dongyang; Zheng, Yue; Tan, Cai‐Ping; Sun, Jinghua; Zhang, Wei; Ji, Liang‐Nian; Mao, Zong‐Wan

doi:10.1021/acsami.6b13808

Cited by 163 publications

(102 citation statements)

References 58 publications

Supporting

Mentioning

102

Contrasting

Order By: Relevance

“…As LysoIr@PDA‐CD‐RGD could localize to lysosomes, the release of cathepsin B from lysosomes was detected using the Magic Red MR‐(RR) 2 assay 20. Control cells display red dot‐like fluorescence mostly localized in lysosomes.…”

Section: Resultsmentioning

confidence: 99%

Delivery of Phosphorescent Anticancer Iridium(III) Complexes by Polydopamine Nanoparticles for Targeted Combined Photothermal‐Chemotherapy and Thermal/Photoacoustic/Lifetime Imaging

et al. 2018

Self Cite

View full text Add to dashboard Cite

Recently, phosphorescent iridium complexes have demonstrated great potential as anticancer and imaging agents. Dopamine is a melanin‐like mimic of mussel adhesive protein that can self‐polymerize to form polydopamine (PDA) nanoparticles that demonstrate favorable biocompatibility, near‐infrared absorption, and photothermal effects. Herein, PDA nanoparticles are functionalized with β‐cyclodextrin (CD) substitutions, which are further assembled with adamantane‐modified arginine‐glycine‐aspartic acid (Ad‐RGD) tripeptides to target integrin‐rich tumor cells. The thus formed PDA‐CD‐RGD nanoparticles can deliver a phosphorescent iridium(III) complexes LysoIr ([Ir(ppy)2(l)]PF6, ppy = 2‐phenylpyridine, L = (1‐(2‐quinolinyl)‐β‐carboline) to form a theranostic platform LysoIr@PDA‐CD‐RGD. It is demonstrated that LysoIr@PDA‐CD‐RGD can be applied for targeted combined cancer photothermal‐chemotherapy and thermal/photoacoustic/two‐photon phosphorescence lifetime imaging under both in vitro and in vivo conditions. This work provides a useful strategy to construct multifunctional nanocomposites for the optimization of metal‐based anticancer agents for further biomedical applications.

show abstract

Section: Resultsmentioning

confidence: 99%

Delivery of Phosphorescent Anticancer Iridium(III) Complexes by Polydopamine Nanoparticles for Targeted Combined Photothermal‐Chemotherapy and Thermal/Photoacoustic/Lifetime Imaging

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, there are other nanomaterials functionalized with Ru(II) complexes for cancer treatments, such as nanographene oxide, 306 polymers, 307 DNA origami and liposomes. 308–311 These Ru(II) complex, functionalized-nanomaterials were safety and efficacious.…”

Section: Ruthenium(ii)-based Nanomaterials Systemsmentioning

confidence: 99%

The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials

et al. 2017

View full text Add to dashboard Cite

Cancer is rapidly becoming the top killer in the world. Most of the FDA approved anticancer drugs are organic molecules, while metallodrugs are very scarce. The advent of first metal based therapeutic agent, cisplatin, launched a new era in the application of transition metal complexes for therapeutic design. Due to their unique and versatile biochemical properties, ruthenium-based compounds have emerged as promising anti-cancer agents that serve as alternatives to cisplatin and its derivertives. The ruthenium(III) complexes have successfully been used in clinical research and their mechanisms of anticancer action have been reported in large volumes over the past few decades. Ruthenium(II) complexes have also attracted significant attention as anticancer candidates; however, only few of them have been reported comprehensively. In this review, we discuss the development of ruthenium(II) complexes as anticancer candidates and biocatalysts, including arene ruthenium complexes, polypyridyl ruthenium complexes, and ruthenium nanomaterial complexes. This review focuses on the likely mechanisms of action of ruthenium(II)-based anticancer drugs and the relationship between their chemical structures and biological properties. This review also highlights the catalytic activity and the photoinduced activation of ruthenium(II) complexes, their targeted delivery, and their activity in nanomaterial systems.

show abstract

“…A nanocomposite of rGO@phosphorescent PEG modified Ru (II) complex (Ru-PEG) also developed and is very effective for both PTT and PDT. This nanocomposite showed high efficacy towards multimodal imaging and treatment of the cancer cells through the generation of ROS [19]. GO-folic acid (FA)/bovine serum albumin (BSA) nanocomposite loaded with DOX showed potential role in treating the cancer cells [20].…”

Section: Drug Delivery and Cancer Therapymentioning

confidence: 99%

Graphene Oxide for Biomedical Applications

K¹,

Modak²,

Paik³

2017

JNMR

View full text Add to dashboard Cite

Graphene oxide (GO) is one of the most promising functional materials used in various applications like energy storage (batteries and supercapacitors) sensors, photocatalysis, electronics and in biomedicine. The last 10 years literature on GO for biomedical applications revealed and confirmed the scope of its potential capabilities as biomaterial. GO alone and its modified form with different materials (surface functionalization, immobilization of nanoparticles and composite formation) also proved as a multifunctional candidate for medical biotechnology. A material for its use in biomedical applications must be biocompatible and nontoxic to the living cells.. Although there are some concerns about the toxicity of the GO in specific cases, a dosage range and size effects reported in the literature to use it as a nontoxic materials. In view of all these points, an effort has been made to review and emphasize the scope of GO as a biomedical agent for the applications like targeted drug delivery, cancer theranostics, bioimaging and biosensors etc. Further, potential applications along with the future scope and limitations of GO have also been highlighted in this review.

show abstract

Graphene Oxide Decorated with Ru(II)–Polyethylene Glycol Complex for Lysosome-Targeted Imaging and Photodynamic/Photothermal Therapy

Cited by 163 publications

References 58 publications

Delivery of Phosphorescent Anticancer Iridium(III) Complexes by Polydopamine Nanoparticles for Targeted Combined Photothermal‐Chemotherapy and Thermal/Photoacoustic/Lifetime Imaging

Delivery of Phosphorescent Anticancer Iridium(III) Complexes by Polydopamine Nanoparticles for Targeted Combined Photothermal‐Chemotherapy and Thermal/Photoacoustic/Lifetime Imaging

The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials

Graphene Oxide for Biomedical Applications

Contact Info

Product

Resources

About